P Lange1, H Scharling, C S Ulrik, J Vestbo. 1. Department of Cardiology and Respiratory Diseases, Hvidovre University Hospital, DK-2650 Hvidovre, Denmark. peter.lange@hh.hosp.dk
Abstract
BACKGROUND: Inhaled corticosteroids (ICS) constitute the cornerstone of treatment for asthma. Many studies have reported beneficial short term effects of these drugs, but there are few data on the long term effects of ICS on the decline in forced expiratory volume in 1 second (FEV(1)). This study was undertaken to determine whether adults with asthma treated with ICS have a less pronounced decline in FEV(1) than those not treated with ICS. METHODS: Two hundred and thirty four asthmatic individuals from a longitudinal epidemiological study of the general population of Copenhagen, Denmark were divided into two groups; 44 were treated with ICS and 190 were not treated with ICS. The annual decline in FEV(1) was measured over a 10 year follow up period. RESULTS: The decline in FEV(1) in the 44 patients receiving ICS was 25 ml/year compared with 51 ml/year in the 190 patients not receiving this treatment (p<0.001). The linear regression model with ICS as the variable of interest and sex, smoking, and wheezing as covariates showed that treatment with ICS was associated with a less steep decline in FEV(1) of 18 ml/year (p = 0.01). Adjustment for additional variables including age, socioeconomic status, body mass index, mucus hypersecretion, and use of other asthma medications did not change these results. CONCLUSIONS: Treatment with ICS is associated with a significantly reduced decline in ventilatory function.
BACKGROUND: Inhaled corticosteroids (ICS) constitute the cornerstone of treatment for asthma. Many studies have reported beneficial short term effects of these drugs, but there are few data on the long term effects of ICS on the decline in forced expiratory volume in 1 second (FEV(1)). This study was undertaken to determine whether adults with asthma treated with ICS have a less pronounced decline in FEV(1) than those not treated with ICS. METHODS: Two hundred and thirty four asthmatic individuals from a longitudinal epidemiological study of the general population of Copenhagen, Denmark were divided into two groups; 44 were treated with ICS and 190 were not treated with ICS. The annual decline in FEV(1) was measured over a 10 year follow up period. RESULTS: The decline in FEV(1) in the 44 patients receiving ICS was 25 ml/year compared with 51 ml/year in the 190 patients not receiving this treatment (p<0.001). The linear regression model with ICS as the variable of interest and sex, smoking, and wheezing as covariates showed that treatment with ICS was associated with a less steep decline in FEV(1) of 18 ml/year (p = 0.01). Adjustment for additional variables including age, socioeconomic status, body mass index, mucus hypersecretion, and use of other asthma medications did not change these results. CONCLUSIONS: Treatment with ICS is associated with a significantly reduced decline in ventilatory function.
Authors: Stanley Szefler; Scott Weiss; James Tonascia; N Franklin Adkinson; Bruce Bender; Reuben Cherniack; Michele Donithan; H William Kelly; Joseph Reisman; Gail G Shapiro; Alice L Sternberg; Robert Strunk; Virginia Taggart; Mark Van Natta; Robert Wise; Margaret Wu; Robert Zeiger Journal: N Engl J Med Date: 2000-10-12 Impact factor: 91.245
Authors: M H Grol; J Gerritsen; J M Vonk; J P Schouten; G H Koëter; B Rijcken; D S Postma Journal: Am J Respir Crit Care Med Date: 1999-12 Impact factor: 21.405
Authors: Stefano Guerra; Duane L Sherrill; Margaret Kurzius-Spencer; Claire Venker; Marilyn Halonen; Stuart F Quan; Fernando D Martinez Journal: Respir Med Date: 2008-08-06 Impact factor: 3.415
Authors: Chad A Witt; Ajay Sheshadri; Luke Carlstrom; Jaime Tarsi; James Kozlowski; Brad Wilson; David S Gierada; Eric Hoffman; Sean B Fain; Janice Cook-Granroth; Geneline Sajol; Oscar Sierra; Tusar Giri; Michael O'Neill; Jie Zheng; Kenneth B Schechtman; Leonard B Bacharier; Nizar Jarjour; William Busse; Mario Castro Journal: Acad Radiol Date: 2014-08 Impact factor: 3.173
Authors: Meyer Balter; Pierre Ernst; Wade Watson; Harold Kim; Lisa Cicutto; Marie-France Beauchesne; Andrew J Cave; Alan Kaplan; Donna Hogg; Andrew McIvor; Tom Smiley; Michel Rouleau; J Mark FitzGerald Journal: Can Respir J Date: 2008 Nov-Dec Impact factor: 2.409
Authors: Loren C Denlinger; Brenda R Phillips; Ronald L Sorkness; Eugene R Bleecker; Mario Castro; Mark D DeBoer; Anne M Fitzpatrick; Annette T Hastie; Jonathan M Gaffin; Wendy C Moore; Michael C Peters; Stephen P Peters; Wanda Phipatanakul; Juan Carlos Cardet; Serpil C Erzurum; John V Fahy; Merritt L Fajt; Benjamin Gaston; Bruce D Levy; Deborah A Meyers; Kristie Ross; W Gerald Teague; Sally E Wenzel; Prescott G Woodruff; Joe Zein; Nizar N Jarjour; David T Mauger; Elliot Israel Journal: Am J Respir Crit Care Med Date: 2021-04-01 Impact factor: 21.405